LabyRx has patents pending on a novel cancer marker and therapeutic target called Labyrinthin*.  Our lead product, LabVax, is a Labyrinthin-derived synthetic peptide vaccine that recruits the body's immune cells to attack adenocarcinomas cancers,  which represent approximately 40% of all cancers and 75% of all cancer deaths.